Taking a new biomarker into routine use - A perspective from the routine clinical biochemistry laboratory

Proteomics - Clinical Applications

Volumn 4, Issue 12, 2010, Pages 892-903

  Sturgeon, Catharine ^a   Hill, Robert ^b   Hortin, Glen L ^c   Thompson, Douglas ^d  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^b SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^d ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Analytical performance; Biomarker efficacy; Biomarker evaluation; Clinical biochemistry; Pre analytical requirements

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; PROSTATE SPECIFIC ANTIGEN;

AUTOMATION; CLINICAL LABORATORY; CLINICAL PRACTICE; CLINICAL PROTOCOL; DIAGNOSTIC VALUE; FUNDING; GOVERNMENT REGULATION; HEALTH CARE SYSTEM; HIGH THROUGHPUT SCREENING; MASS SPECTROMETRY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEOMICS; QUALITY CONTROL; REPRODUCIBILITY; REVIEW; STANDARDIZATION; UNITED KINGDOM; UNITED STATES;

AGED; AUTOMATION, LABORATORY; BIOLOGICAL MARKERS; CLINICAL LABORATORY TECHNIQUES; COST-BENEFIT ANALYSIS; DIAGNOSTIC TEST APPROVAL; FEMALE; HUMANS; MALE; PROTEOMICS; SPECIMEN HANDLING; VALIDATION STUDIES AS TOPIC;

EID: 78449290052     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201000073     Document Type: Review

References (37)

1. Anderson, N. L., The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin. Chem. 2010, 56, 177-185.
2. Hortin, G. L., Jortani, S. A., Ritchie, J. C., Jr., Valdes, R., Jr., Chan, D. W., Proteomics: a new diagnostic frontier. Clin. Chem. 2006, 52, 1218-1222.
3. Beastall, G. H., The Modernisation of pathology and laboratory medicine in the UK: networking into the future. Clin. Biochem. Rev. 2008, 29, 3-10.
4. Panteghini, M., Improving the clinical value of laboratory information and permitting a common global approach to diseases. Foreword. Scand. J. Clin. Lab. Invest. Suppl. 2010, 242, 3.
5. Ablin, R. J., Soanes, W. A., Bronson, P., Witebsky, E., Precipitating antigens of the normal human prostate. J. Reprod. Fertil. 1970, 22, 573-574.
6. Stamey, T. A., Yang, N., Hay, A. R., McNeal, J. E. et al., Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J. Med. 1987, 317, 909-916.
7. Rafferty, B., Rigsby, P., Rose, M., Stamey, T., Gaines Das, R., Reference reagents for prostate-specific antigen (PSA): establishment of the first international standards for free PSA and PSA (90:10). Clin. Chem. 2000, 46, 1310-1317.
8. Fryer, A. A., Hanna, F. W., Managing demand for pathology tests: financial imperative or duty of care? Ann. Clin. Biochem. 2009, 46, 435-437.
9. Department of Health. Equity and excellence: liberating the NHS. UK Dept of Health White Paper 2010.
10. Ransohoff, D. F., How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design. J. Clin. Epidemiol. 2007, 60, 1205-1219.
11. Ransohoff, D. F., Gourlay, M. L., Sources of bias in specimens for research about molecular markers for cancer. J. Clin. Oncol. 2010, 28, 698-704.
12. Hemingway, H., Riley, R. D., Altman, D. G., Ten steps towards improving prognosis research. Br. Med. J. 2009, 339, 410-414.
13. Vaught, J. B., Caboux, E., Hainaut, P., International efforts to develop biospecimen best practices. Cancer Epidemiol. Biomarkers Prev. 2010, 19, 912-915.
14. Jackson, D. H., Banks, R. E., Banking of clinical samples for proteomic biomarker studies: a consideration of logistical issues with a focus on pre-analytical variation. Proteomics Clin. Appl. 2010, 4, 250-270.
15. Elliott, P., Peakman, T. C., On behalf of UK Biobank, The UK Biobank sample handling and storage protocol for the collection, processing and archiving of human blood and urine. Int. J. Epidemiol. 2008, 37, 234-244.
16. Fraser, C. G., Inherent biological variation and reference values. Clin. Chem. Lab. Med. 2004, 42, 758-764.
17. Davies, C., in: Wild, D. (Ed.), The Immunoassay Handbook, 2nd Edn, Nature Publishing, Basingstoke 2001, pp. 78-110.
18. Doust, J., Qualification versus validation of biomarkers. Scand. J. Clin. Lab. Invest. Suppl. 2010, 242, 40-43.
19. Sturgeon, C. M., Ellis, A. R., Standardization of FSH, LH and hCG - current position and future prospects. Mol. Cell. Endocrinol. 2007, 260-262, 301-309.
20. Price, C. P., Martin, L., Novel markers, a payer's perspective: commissioning a new service. Scand. J. Clin. Lab. Invest. Suppl. 2010, 242, 103-108.
21. Scott, M. G., When do new biomarkers make economic sense? Scand. J. Clin. Lab. Invest. Suppl. 2010, 242, 90-95.
22. Khatami, Z., Hill, R., Sturgeon, C. M., Kearney, E. et al., Measurement verification in the clinical laboratory [Association for Clinical Biochemistry]. UK Association for Clinical Biochemistry. 2005, .
23. Sturgeon, C. M., Hoffman, B. R., Chan, D. W., Ch'ng, S. L. et al., National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements. Clin. Chem. 2008, 54, e1-e10.
24. Bruns, D. E., Boyd, J. C., Assessing the impact of biomarkers on patient outcome: an obligatory step. Scand. J. Clin. Lab. Invest. Suppl. 2010, 242, 85-89.
25. Mallett, S., Timmer, A., Sauerbrei, W., Altman, D. G., Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines. Br. J. Cancer 2010, 102, 173-180.
26. Viswanathan, K., Kilcullen, N., Morrell, C., Thistlethwaite, S. J. et al., Heart-type fatty acid-binding protein predicts long-term mortality and re-infarction in consecutive patients with suspected acute coronary syndrome who are troponin-negative. J. Am. Coll. Cardiol. 2010, 55, 2590-2598.
27. Begg, C., Cho, M., Eastwood, S., Horton, R. et al., Improving the quality of reporting of randomized controlled trials. The CONSORT statement. J. Am. Med. Assoc. 1996, 276, 637-639.
28. Roddam, A. W., Price, C. P., Allen, N. E., Ward, A. M., Assessing the clinical impact of prostate-specific antigen assay variability and nonequimolarity: a simulation study based on the population of the United Kingdom. Clin. Chem. 2004, 50, 1012-1016.
29. Boyd, J. C., Bruns, D. E., Monte Carlo simulation in establishing analytical quality requirements for clinical laboratory tests meeting clinical needs. Methods Enzymol. 2009, 467, 411-433.
30. Lord Carter of Coles. Report of the review of NHS pathology services in England, UK Dept of Health 2006, .
31. Michie, S., Johnston, M., Changing clinical behaviour by making guidelines specific. Br. Med. J. 2004, 328, 343-345.
32. Hutton, H. D., Drummond, H. S., Fryer, A. A., The rise and fall of C-reactive protein: managing demand within clinical biochemistry. Ann. Clin. Biochem. 2009, 46, 155-158.
33. Metcalfe, T. A., Development of novel IVD assays: a manufacturer's perspective. Scand. J. Clin. Lab. Invest. Suppl. 2010, 242, 23-26.
34. Rajappan, K., Murphy, E., Amber, V., Meakin, F. et al., Usage of troponin in the real world: a lesson for the introduction of biochemical assays. Q. J. Med. 2005, 98, 337-342.
35. Hlatky, M. A., Greenland, P., Arnett, D. K., Ballantyne, C. M. et al., Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 2009, 119, 2408-2416.
36. Hortin, G. L., Can mass spectrometric protein profiling meet desired standards of clinical laboratory practice? Clin. Chem. 2005, 51, 3-5.
37. Sackett, D. L., Haynes, R. B., The architecture of diagnostic research. Br. Med. J. 2002, 324, 539-541.